THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy.

MAP Podcast

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.

Podcast available on:

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!

🚀 Dive Deep into the Core of Pharmaceutical Reforms!

Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀


🌎 Explore the Global Impact!

Navigate through their insightful discussion on how these reforms potentially sculpt Germany’s presence on the global stage, especially in the orphan drugs market, and assess Germany's unique positioning in evaluating them! 🌎


💡 Illuminating the Opaqueness of Drug Pricing!

Embark on a journey through the complexities and pragmatic implications of drug pricing, dissecting the nuances of arbitration boards, pricing mechanisms, and the often intricate physician prescription behaviors amidst the recent reforms. 💡


🤔 Facing the Challenges Head-On!

Explore the potential disconnect between pricing strategies and actual prescription practices, as our experts shed light on the vital need for enhancing transparency and communication with physicians regarding pricing negotiations and adjustments. 🤔


👥 Join Matthias and Stefan as they scrutinize the germane issues of drug pricing, contemplate future adjustments within the system, and ponder upon the possible shifts influenced by the upcoming national elections and continual changes within the healthcare landscape! 👥


🎧 Tune in to immerse yourself in a conversation that not only explores the multidimensional aspects of the healthcare and pharmaceutical reimbursement system but also poses potent questions regarding its future amidst regulatory and structural shifts! 🎧


A journey through the dynamics of pharmaceutical pricing and reforms awaits you, amplifying both economic and patient care perspectives amidst the shifting tides of the healthcare system in Germany! Don’t miss it! 🚀🚀

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

 

Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“. 

Dr. Heiner Sandmeier has been part of the drug evaluation committee advising the Swiss decision makers for over a century and opens his insights and secrets to all listeners. 

Some of the topics Dr. Sandmeier and reimbursement veteran Dr. Stefan Walzer discuss are as follows: 

  • What are the main drivers for a positive decision in Switzerland?
  • Who is involved in the decision process?
  • What are the challenges as well as possible solutions for the main issues?
  • What are the differences to other countries in Europe?

And last but not least: Why should you still consider to enter the Swiss market with an innovative pharmaceutical product?


✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb


MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #pricingstrategy #negotiations #pricing #pharmaceuticals #switzerland #innovation #reimbursement

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:

- What are the differences between Clinical Development and Medical Affairs?

- When should a company start telling their medical story about a new product?

- What are the differences between drugs and vaccinations from a medical affairs’ perspective?

- And how should market access and medical affairs ideally work together?

Market access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access continued their come together in Boston in May 2023 in this epic podcast episode. 

Don’t miss this amazing conversation. 

 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #medicalaffairs #pricingstrategy #negotiations

#pricing #medtech #pharmaceuticals #usa #innovation #vaccination